Skip to main content

Navigation group

Type at least 3 characters
1,331 articles

Articles

Original Research

Published on 29 Oct 2024

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

in Cancer Immunity and Immunotherapy

  • Toshio Shimizu
  • John Powderly
  • Albiruni Abdul Razak
  • Patricia LoRusso
  • Kathy D. Miller
  • Steven Kao
  • Sarah Kongpachith
  • Catherine Tribouley
  • Michelle Graham
  • Brian Stoll
Frontiers in Oncology
doi 10.3389/fonc.2024.1376551
  • 906 views